Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 9/20 | 0.80 |
| ▸ | FNTB | P49356 | 9/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.62 |
| ▸ | RORC | P51449 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5722541 | 0.92 | FNTA (0.78) | FNTAFNTBCYP3A4RORC | |
| SCHEMBL12022163 | 0.92 | FNTA (0.78) | FNTAFNTBCYP3A4RORC | |
| SCHEMBL5722562 | 0.92 | FNTA (0.78) | FNTAFNTBCYP3A4RORC | |
| SCHEMBL7256220 | 0.92 | FNTA (0.78) | FNTAFNTBCYP3A4RORC | |
| SCHEMBL4294372 | 0.92 | FNTA (0.78) | FNTAFNTBCYP3A4RORC | |
| SCHEMBL12022161 | 0.92 | FNTA (0.78) | FNTAFNTBCYP3A4RORC | |
| SCHEMBL1643357 | 0.92 | FNTA (0.78) | FNTAFNTBCYP3A4RORC | |
| Cp-609754 SCHEMBL4277842 | 0.91 | FNTA (0.81) | FNTAFNTBCYP3A4RORC | |
| Cp-609754 SCHEMBL30481066 | 0.91 | FNTA (0.81) | FNTAFNTBCYP3A4RORC | |
| Cp-609754 SCHEMBL21055098 | 0.91 | FNTA (0.81) | FNTAFNTBCYP3A4RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579887-B2 | Effective in inhibiting farnesyl protein transferase; also useful in treating benign proliferative disease. | PFIZER INC | 2003-06-17 | — | — | US | disclosed |
| US-20020128287-A1 | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents | LYSSIKATOS JOSEPH P (US) | 2002-09-12 | — | — | US | disclosed |
| US-6294552-B1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS, SUCH AS CANCER, IN MAMMALS. THE INVENTION ALSO RELATES TO METHODS OF INHIBITING ABNORMAL CELL GROWTH, INCLUDING CANCER, IN A MAMMAL BY ADMINISTERING THE COMPOUNDS OF FORMULA 1 TO A MAMMAL REQUIRING | PFIZER INC. | 2001-09-25 | — | — | US | disclosed |
| US-6150377-A | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents | PFIZER INC. (US) | 2000-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128287-A1 | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents | CCNA1, NRAS, CCNT1 | FNTA 1890/4885FNTB 2727/4885CYP3A4 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.